Form 4: Gregory Kazarian receives 2,000 RSUs at P3 Health Partners
Rhea-AI Filing Summary
P3 Health Partners Inc. director Gregory N. Kazarian was granted 2,000 restricted stock units (RSUs) on 08/06/2025, reported on a Form 4. Each RSU represents a right to receive one share of Class A common stock under the company’s 2021 Incentive Award Plan and the RSUs vest one year from the grant date. The award is reported with a $0 price as an equity grant and is coded as an acquisition.
After the grant Mr. Kazarian is reported to directly beneficially own 218,561 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 08/08/2025. No derivative securities are reported in Table II of the filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small RSU award to a director increases direct holdings to 218,561 shares; vests in one year and was reported on Form 4.
The disclosure documents a routine director equity award: 2,000 RSUs granted under the 2021 Incentive Award Plan, each convertible to one share and vesting in one year. The filing shows direct beneficial ownership of 218,561 shares post-grant and records the acquisition at $0 as an award. This appears to be a standard compensation-related grant rather than a market purchase or sale; the filing contains no derivative transactions. From a governance perspective, the award signals alignment with equity compensation practices but is modest in size relative to the reported holdings and does not, by itself, indicate a material change in ownership or control.
TL;DR: The 2,000 RSU grant vests after one year; economically it is a time-based award with limited immediate dilution or cash impact.
The grant is recorded as restricted stock units that vest one year from the grant date and are reported at a $0 issuance price, consistent with typical time-based RSU awards. The increment of 2,000 shares is small relative to the reported direct holdings of 218,561 shares, implying limited near-term dilution and modest incremental executive equity retention. The Form 4 shows no related option or derivative activity. This looks like routine compensation administration rather than a performance-triggered or transaction-driven event.